Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus.
about
Clinical Implications of Antiviral Resistance in InfluenzaPotential strategies and biosafety protocols used for dual-use research on highly pathogenic influenza virusesInhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion proteinIota-carrageenan is a potent inhibitor of influenza A virus infectionAvian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving targetThe effects of neuraminidase inhibitors on the release of oseltamivir-sensitive and oseltamivir-resistant influenza viruses from primary cultures of human tracheal epithelium.How I treat influenza in patients with hematologic malignancies.Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients.In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.Caveolin-1 influences human influenza A virus (H1N1) multiplication in cell culture.Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia.Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit.Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model systemChanging epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients.Perspective: emerging challenges in the treatment of influenza and parainfluenza in transplant patientsEpidemiological analysis of critically ill adult patients with pandemic influenza A(H1N1) in South Korea.PATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries.Nosocomial outbreak of the pandemic Influenza A (H1N1) 2009 in critical hematologic patients during seasonal influenza 2010-2011: detection of oseltamivir resistant variant viruses.Reassortment and mutations associated with emergence and spread of oseltamivir-resistant seasonal influenza A/H1N1 viruses in 2005-2009.Clinical importance and impact on the households of oseltamivir-resistant seasonal A/H1N1 influenza virus in healthy children in Italy.Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181.Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient.Outbreak of antiviral drug-resistant influenza a in long-term care facility, Illinois, USA, 2008.Can newly developed, rapid immunochromatographic antigen detection tests be reliably used for the laboratory diagnosis of influenza virus infections?Influenza A(H1N1) Oseltamivir Resistant Viruses in the Netherlands During the Winter 2007/2008.Phosphatidylglycerol suppresses influenza A virus infectionSafety of oseltamivir compared with the adamantanes in children less than 12 months of age.Transcriptomics and proteomics in the study of H1N1 2009.Influenza pharmacotherapy: present situation, strategies and hopes.A review of neuraminidase inhibitor susceptibility in influenza strains.Genetic makeup of amantadine-resistant and oseltamivir-resistant human influenza A/H1N1 viruses.Emerging influenza antiviral resistance threats.Molecular characteristics of outbreaks of nosocomial infection with influenza A/H3N2 virus variants.A successful mandatory influenza vaccination campaign using an innovative electronic tracking system.Patient and family education in HSCT: improving awareness of respiratory virus infection and influenza vaccination. A descriptive study and brief intervention.Comparisons of oseltamivir-resistant (H275Y) and concurrent oseltamivir-susceptible seasonal influenza A(H1N1) virus infections in hospitalized adults, 2008-2009.Role of neuraminidase inhibitor chemoprophylaxis in controlling nosocomial influenza: an observational study.Automated Real-Time Collection of Pathogen-Specific Diagnostic Data: Syndromic Infectious Disease EpidemiologyAnti-influenza therapy: the emerging challenge of resistance
P2860
Q26782746-2F66787C-1626-4B45-811B-4704E1299F1FQ26825532-4E489DD8-7B6E-4392-B4D0-6BE052445A7FQ28471835-CD3BCDE8-41C3-4CC2-B479-1B8F7CDF2F1BQ28744254-6270E0E4-94C7-49B2-AD89-B3B02B7907F4Q30227194-40314D50-AE21-478E-9067-BE73C9A08249Q30362682-F7FF81E4-4B96-448C-80BD-D09875B0A0D3Q30383456-AB108654-3EDC-47EE-B85C-796D415F29A0Q30386485-C618AFEF-B331-4190-BA0E-E8F566C987E5Q30387420-B1569FE9-B0C5-4F9F-B552-4918DD3E7648Q30389699-96A70C78-E599-40F4-9237-0ECC0C9FE5ADQ30390856-397529F0-2B50-40D2-99E3-9A244460C726Q30397250-D149D071-ECF1-4211-BD97-06E2CD304B78Q30398935-2F44CE95-5900-43D8-B661-9EFCBFCB5B71Q30403699-DB3B38E7-2E74-48B8-BE29-842012061BC0Q30412678-E58AB859-87C6-4655-9D8D-85A94E09AF60Q30419932-5067A5C5-52A1-429B-81DE-5EDE57BACDF8Q30421549-FB8E58FA-6F9F-4A94-AFDF-EC6233ED850DQ30428311-D25C6FCF-12D6-4B83-B792-5A19F62B9044Q33869689-075E337F-A7B3-4B84-991B-2793B20B365DQ34128268-2C541EC3-B53E-4B25-902A-2AC86429C3E6Q34405859-45116068-6AC9-4348-B481-B41CF193C59EQ34597785-5BAF83A1-D969-4A81-B921-F32103BFFD98Q34603566-0437DB03-A500-4C36-82F8-04656BD61AB3Q35607432-40E43A5C-4A89-45BB-A18F-3716E8D9B5E2Q35645982-21BDBDA3-7810-44EA-8C32-8F1538CB3D4DQ35987319-713FFC01-07AD-4B37-A8DB-2C9542F97B1AQ36990293-97A9AA8F-FBEA-474F-9E80-535C4A93C107Q37318402-EDDCEF8C-130F-4817-B051-B3E83C3C3CD2Q37857854-2B508FF4-F941-4196-9611-7CAEB779A0DEQ38258646-DA655B9C-63CB-4D9C-AD3F-389CE6ABFA5EQ39900826-5D2810E6-2264-488F-A15A-9A856EBB4A47Q42725866-A1D5B9F6-3ADD-47F2-B384-F42091B48276Q43173055-A9CC0A72-F9DC-49AB-8A14-C57794C48C4FQ43445109-C3D8C485-C73D-4F74-9DED-E3F7EDA0426FQ44221746-EE3A6DB3-44B9-49FD-898C-92C4E2FBC463Q45356909-0EE2CAB0-2624-4B6E-824C-5542F9DD924DQ49163840-9C5D7CAD-5414-4C82-80A2-64484EBDA529Q56536622-6B663CAA-47DC-4026-AE11-CEDAA2AFADF3Q58066873-8CC07002-9133-4576-9DD5-530505BD1F1A
P2860
Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Morbidity and mortality associ ...... ltamivir-resistant influenza A
@nl
Morbidity and mortality associ ...... stant influenza A(H1N1) virus.
@en
type
label
Morbidity and mortality associ ...... ltamivir-resistant influenza A
@nl
Morbidity and mortality associ ...... stant influenza A(H1N1) virus.
@en
prefLabel
Morbidity and mortality associ ...... ltamivir-resistant influenza A
@nl
Morbidity and mortality associ ...... stant influenza A(H1N1) virus.
@en
P2093
P356
P1476
Morbidity and mortality associ ...... stant influenza A(H1N1) virus.
@en
P2093
Adam Meijer
Aloyj M Kroes
Eric C J Claas
Jairo Gooskens
Peterhans J van den Broek
P304
P356
10.1001/JAMA.2009.297
P407
P577
2009-03-02T00:00:00Z